FDA’s Division of Anesthesia, Analgesia and Addiction Products will be moving into the post-Zohydro era with a new director.
Sharon Hertz, the deputy in the division, was elevated to Acting Director at the start of October, upon the retirement...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?